A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies
NCT05567887
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
7
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma
Multiple Myeloma
Interventions
DRUG:
maplirpacept (PF-07901801)
Sponsor
Pfizer